Literature DB >> 707490

Estimating exposure-specific disease rates from case-control studies using Bayes' theorem.

R R Neutra, M E Drolette.   

Abstract

The methods used for selecting subjects yield three types of case-control studies: 1) incident cases are compared to non-cases chosen to be representative of the exposure distribution among the person-years which produced the cases. In this type of study the exposure-odds ratio equals the incidence density ratio; 2) incident cases are compared to residual non-cases at the end of the risk period (exposure-odds ratio = cumulative incidence-odds ratio); 3) prevalent cases are compared to non-cases (exposure-odds ratio = prevalence odds ratio). In study type 1 the equivalence of odds ratio to rate ratio requires no "rare disease assumption;" this permits estimation of exposure-specific illness rates when the overall rate is known. In study types 2 and 3 the exposure-odds ratio equals the corresponding rate ratios only when exposure-specific rates are low. Nonetheless, exposure-specific rates can be calculated without making any rare disease assumption using Bayes' theorem and information on the overall disease rate. A method for obtaining approximate confidence limits around the exposure-specific rates is presented.

Entities:  

Mesh:

Year:  1978        PMID: 707490     DOI: 10.1093/oxfordjournals.aje.a112614

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  2 in total

1.  IDDM susceptibility associated with polymorphisms in the insulin gene region. A study of blacks, Caucasians and orientals.

Authors:  D E Undlien; K Hamaguchi; A Kimura; E Tuomilehto-Wolf; A B Swai; D G McLarty; J Tuomilehto; E Thorsby; K S Rønningen
Journal:  Diabetologia       Date:  1994-08       Impact factor: 10.122

2.  Testing for Sufficient-Cause Interactions in Case-Control Studies of Non-Rare Diseases.

Authors:  Jui-Hsiang Lin; Wen-Chung Lee
Journal:  Sci Rep       Date:  2018-06-18       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.